The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study
Open accessPublished version of a preprint
Abstract
Objectives: To determine whether time elapsed since the second injection of the Pfizer-BioNTech BNT162b2 mRNA vaccine was significantly associated with the risk of covid-19 infection after vaccination in people who received two vaccine injections. Design: Test negative design study. Setting: Electronic health records of a large state mandated healthcare organisation, Israel. Participants: Adults aged ≥18 years who had received a reverse transcription polymerase chain reaction (RT-PCR) test between 15 May 2021 and 17 September 2021, at least three weeks after their second vaccine injection, had not received a third vaccine injection, and had no history of covid-19 infection. Main outcome measures: Positive result for the RT-PCR test. Individuals who tested positive for SARS-CoV-2 and controls were matched for week of testing, age category, and demographic group (ultra-orthodox Jews, individuals of Arab ancestry, and the general population). Conditional logistic regression was adjusted for age, sex, socioeconomic status, and comorbid conditions. Results: 83 057 adults received an RT-PCR test for SARS-CoV-2 during the study period and 9.6% had a positive result. Time elapsed since the vaccine injection was significantly longer in individuals who tested positive (P<0.001). Adjusted odds ratio for infection at time intervals >90 days since vaccination were significantly increased compared with the reference of <90 days: 2.37 (95% confidence interval 1.67 to 3.36) for 90-119 days, 2.66 (1.94 to 3.66) for 120-149 days, 2.82 (2.07 to 3.84) for 150-179 days, and 2.82 (2.07 to 3.85) for ≥180 days (P<0.001 for each 30 day interval). Conclusions: In this large population of adults tested for SARS-CoV-2 by RT-PCR after two doses of mRNA BNT162b2 vaccine, a gradual increase in the risk of infection was seen for individuals who received their second vaccine dose after at least 90 days.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“protection against infection starts to wane within a few months of administration.8–11”
From Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis (2023) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
Perineuronal nets stabilize the grid cell network
Christensen, A. C., Lensjø, K. K., Lepperød, M. E., Dragly, S.-A., Sutterud, H., Blackstad, J. S., Fyhn, M., & Hafting, T. (2021) · Nature Communications · doi:10.1038/s41467-020-20241-w · Cited by 1,865
Evolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034545 · Cited by 940
Cutting edge: long-term B cell memory in humans after smallpox vaccination
Crotty, S., Felgner, P., Davies, H., Glidewell, J., Villarreal, L., & Ahmed, R. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.10.4969 · Cited by 695
Looking beyond COVID-19 vaccine phase 3 trials
Kim, J. H., Marks, F., & Clemens, J. D. (2021) · Nature Medicine · doi:10.1038/s41591-021-01230-y · Cited by 601
Bajaj, V., Gadi, N., Spihlman, A. P., Wu, S. C., Choi, C. H., & Moulton, V. R. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2020.571416 · Cited by 476
Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19
Wheatley, A. K., Juno, J. A., Wang, J. J., Selva, K. J., Reynaldi, A., Tan, H.-X., Lee, W. S., Wragg, K. M., Kelly, H. G., Esterbauer, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21444-5 · Cited by 351
Research works printed but not linked: 1
- 10.1101/2021.08.19.21262111 · DOI
Cited by
Sorted by citations
Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., et al. (2021) · doi:10.1101/2021.12.14.21267615 · Cited by 2,420
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
Goel, R. R., Painter, M. M., Apostolidis, S. A., Mathew, D., Meng, W., Rosenfeld, A. M., Lundgreen, K. A., Reynaldi, A., Khoury, D. S., Pattekar, A., et al. (2021) · Science · doi:10.1126/science.abm0829 · Cited by 873
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
Chemaitelly, H., Tang, P., Hasan, M. R., AlMukdad, S., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114114 · Cited by 831
Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines
Andrews, N., Tessier, E., Stowe, J., Gower, C., Kirsebom, F., Simmons, R., Gallagher, E., Thelwall, S., Groves, N., Dabrera, G., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115481 · Cited by 807
Pouwels, K. B., Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Vihta, K.-D., House, T., Hay, J., Bell, J. I., Newton, J. N., et al. (2021) · doi:10.1101/2021.08.18.21262237 · Cited by 543
Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Sachdeva, R., Gower, C., Ramsay, M., & Lopez Bernal, J. (2022) · Nature Medicine · doi:10.1038/s41591-022-01699-1 · Cited by 453
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
Tang, P., Hasan, M. R., Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., AlMukdad, S., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01583-4 · Cited by 450
McMenamin, M. E., Nealon, J., Lin, Y., Wong, J. Y., Cheung, J. K., Lau, E. H. Y., Wu, P., Leung, G. M., & Cowling, B. J. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00345-0 · Cited by 360
Mucosal Immune Response in BNT162b2 COVID-19 Vaccine Recipients
Azzi, L., Gasperina, D. D., Veronesi, G., Shallak, M., Ietto, G., Iovino, D., Baj, A., Gianfagna, F., Maurino, V., Focosi, D., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103788 · Cited by 225
Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection
Israel, A., Shenhar, Y., Green, I., Merzon, E., Golan‐Cohen, A., Schäffer, A. A., Ruppin, E., Vinker, S., & Magen, E. (2021) · Vaccines · doi:10.3390/vaccines10010064 · Cited by 225
Self-citationResurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce
Keehner, J., Horton, L. E., BINKIN, N. J., Laurent, L. C., Pride, D. T., Longhurst, C., Abeles, S. R., & Torriani, F. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2112981 · Cited by 155
Feikin, D. R., Higdon, M. M., Abu-Raddad, L. J., Andrews, N. J., Rafael Araos, B., Goldberg, Y., Groome, M. J., Huppert, A., O’Brien, K. L., Smith, P. G., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3961378 · Cited by 144
Fabiani, M., Puopolo, M., Morciano, C., Spuri, M., Alegiani, S. S., Filia, A., D’Ancona, F. “., Manso, M. D., Riccardo, F., Tallon, M., et al. (2022) · BMJ · doi:10.1136/bmj-2021-069052 · Cited by 111
Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V. X., Frankland, T. B., Ackerson, B. K., Takhar, H. S., Ogun, O. A., Simmons, S. R., Zamparo, J. M., et al. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100198 · Cited by 107
The Global Impact of COVID-19 on Solid Organ Transplantation: Two Years Into a Pandemic
Nimmo, A., Gardiner, D. D., Ushiro‐Lumb, I., Ravanan, R., & Forsythe, J. L. R. (2022) · Transplantation · doi:10.1097/tp.0000000000004151 · Cited by 104
Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review
Pooley, N., Karim, S. S. A., Combadière, B., Ooi, E. E., Harris, R. C., Guerche‐Séblain, C. E., Kisomi, M., & Shaikh, N. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00753-2 · Cited by 95
SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort
Aldridge, R. W., Yavlinsky, A., Nguyen, V. G., Eyre, M. T., Shrotri, M., Navaratnam, A. M. D., Beale, S., Braithwaite, I., Byrne, T., Kovar, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32265-5 · Cited by 84
Abu-Raddad, L. J., Chemaitelly, H. S., Ayoub, H. H., Tang, P., Coyle, P. V., Hasan, M. R., Yassine, H. M., Benslimane, F. M., Al-Khatib, H. A., Kanaani, Z. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28199-7 · Cited by 80
Monge, S., Rojas-Benedicto, A., Olmedo, C., Mazagatos, C., José Sierra, M., Limia, A., Martín-Merino, E., Larrauri, A., Hernán, M. A., Moreno, D., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00292-4 · Cited by 81
Omicron variant: Current insights and future directions
Rana, R., Kant, R., Huirem, R. S., Bohra, D., & Ganguly, N. K. (2022) · Microbiological Research · doi:10.1016/j.micres.2022.127204 · Cited by 83
Goel, R. R., Painter, M. M., Apostolidis, S. A., Mathew, D., Meng, W., Rosenfeld, A. M., Lundgreen, K. A., Reynaldi, A., Khoury, D. S., Pattekar, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.23.457229 · Cited by 59
Barrière, J., Carlès, M., Audigier-Valette, C., Ré, D., Adjtoutah, Z., Seitz‐Polski, B., Gounant, V., Descamps, D., & Zalcman, G. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.12.011 · Cited by 56
Huang, A., Cicin‐Sain, C., Pasin, C., Epp, S., Audigé, A., Mueller, N. J., Nilsson, J., Bankova, A. K., Wolfensberger, N., Vilinovszki, O., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.01.019 · Cited by 55
Duration of immunity following full vaccination against SARS-CoV-2: a systematic review
Addo, I. Y., Dadzie, F. A., Okeke, S. R., Boadi, C., & Boadu, E. F. (2022) · Archives of Public Health · doi:10.1186/s13690-022-00935-x · Cited by 58
Stouten, V., Hubin, P., Haarhuis, F., van Loenhout, J. A. F., Billuart, M., Brondeel, R., Braeye, T., Oyen, H. J. V., Wyndham-Thomas, C., & Catteau, L. (2022) · Viruses · doi:10.3390/v14040802 · Cited by 45
Kappelman, M. D., Weaver, K. N., Zhang, X., Dai, X., Watkins, R. D., Adler, J., Dubinsky, M. C., Kastl, A., Bousvaros, A., Strople, J. A., et al. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001619 · Cited by 42
Wirawan, G. B. S., Harjana, N. P. A., Nugrahani, N. W., & Januraga, P. P. (2022) · Vaccines · doi:10.3390/vaccines10050724 · Cited by 43
Bonnet, B., Chabrolles, H., Archimbaud, C., Brebion, A., Cosme, J., Dutheil, F., Lambert, C., Junda, M., Mirand, A., Ollier, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.842912 · Cited by 43
A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines
He, X., Su, J., Ma, Y., Zhang, W., & Tang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.945930 · Cited by 41
Gilboa, M., Mandelboim, M., Indenbaum, V., Lustig, Y., Cohen, C., Rahav, G., Asraf, K., Amit, S., Jaber, H., Nemet, I., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab584 · Cited by 38
Mongin, D., Bürgisser, N., Laurie, G., Schimmel, G., Vu, D., Cullati, S., Covid-SMC Study Group, Mora, L. D. S., Després, L., Dudouit, R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41109-9 · Cited by 40
Double Negative Control Inference in Test-Negative Design Studies of Vaccine Effectiveness
Li, K. Q., Shi, X., Miao, W., & Tchetgen, E. T. (2023) · Journal of the American Statistical Association · doi:10.1080/01621459.2023.2220935 · Cited by 41
Almendro-Vázquez, P., Chivite‐Lacaba, M., Utrero‐Rico, A., González‐Cuadrado, C., Laguna‐Goya, R., Moreno-Batanero, M., Sánchez-Paz, L., Luczkowiak, J., Labiod, N., Folgueira, M. D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.981350 · Cited by 37
The Repeated Setbacks of HIV Vaccine Development Laid the Groundwork for SARS-CoV-2 Vaccines
Harris, J. E. (2021) · National Bureau of Economic Research · doi:10.3386/w28587 · Cited by 37
mRNA COVID-19 Vaccines and Long-Lived Plasma Cells: A Complicated Relationship
Giannotta, G., & Giannotta, N. (2021) · Vaccines · doi:10.3390/vaccines9121503 · Cited by 33
Harris, J. E. (2021) · Health Policy and Technology · doi:10.1016/j.hlpt.2021.100583 · Cited by 34
Single-shot AAV-vectored vaccine against SARS-CoV-2 with fast and long-lasting immunity
Wu, F., Luo, S., Zhang, Y., Ou, Y., Wang, H., Guo, Z., He, C., Bai, S., He, P., Jiang, M., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.07.004 · Cited by 35
Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records
Niesen, M. J. M., Pawlowski, C., O’Horo, J. C., Challener, D. W., Silvert, E., Donadio, G., Lenehan, P. J., Virk, A., Swift, M. D., Speicher, L. L., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.7038 · Cited by 33
Lechmere, T., Snell, L. B., Graham, C., Seow, J., Shalim, Z. A., Charalampous, T., Alcolea-Medina, A., Batra, R., Nebbia, G., Edgeworth, J. D., et al. (2022) · mBio · doi:10.1128/mbio.03798-21 · Cited by 30
Braeye, T., Catteau, L., Brondeel, R., van Loenhout, J. A. F., Proesmans, K., Cornelissen, L., Oyen, H. J. V., Stouten, V., Hubin, P., Billuart, M., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.025 · Cited by 33
Vaccine Effectiveness of Two and Three Doses of BNT162b2 and Coronavac Against COVID-19 in Hong KongPreprint
McMenamin, M. E., Nealon, J., Lin, Y., Wong, J. Y., Cheung, J. K., Lau, E. H. Y., Wu, P., Leung, G. M., & Cowling, B. J. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4064649 · Cited by 32
Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection
Puranik, A., Lenehan, P. J., Silvert, E., Niesen, M. J. M., Corchado-García, J., O’Horo, J. C., Virk, A., Swift, M. D., Gordon, J. E., Speicher, L. L., et al. (2021) · Med · doi:10.1016/j.medj.2021.12.002 · Cited by 31
Rahman, M. O., Kamigaki, T., Thandar, M. M., Haruyama, R., Yan, F., Shibamura-Fujiogi, M., Khin Maung Soe, J., Islam, M. R., Yoneoka, D., Miyahara, R., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-076892 · Cited by 29
Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine
Coléon, S., Wiedemann, A., Surénaud, M., Lacabaratz, C., Hüe, S., Prague, M., Cervantes-Gonzalez, M., Wang, Z., Ellis, J., Sansoni, A., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104062 · Cited by 29
Andrejko, K. L., Pry, J. M., Myers, J. F., Mehrotra, M., Lamba, K., Lim, E., Fukui, N., DeGuzman, J. L., Openshaw, J., Watt, J., et al. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad017 · Cited by 28
Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination
Jo, D. H., Minn, D., Lim, J., Lee, K.-D., Kang, Y. M., Choe, K. W., & Kim, K. N. (2021) · Vaccines · doi:10.3390/vaccines9101145 · Cited by 32
Lee, C., Gray, V., Teo, J. M. N., Tam, A. R., Fong, C. H.-Y., Lui, D. T. W., Pang, P., Chan, K. H., Hung, I. F., Tan, K. C. B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018393 · Cited by 26
Mohapatra, R. K., El-Shall, N. A., Tiwari, R., Nainu, F., Kandi, V., Sarangi, A. K., Mohammed, T. A., Desingu, P. A., Chakraborty, C., & Dhama, K. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2065824 · Cited by 27
Paramithiotis, E., Sugden, S., Papp, E., Bonhomme, M., Chermak, T., Crawford, S. Y., Demetriades, S. Z., Galdos, G., Lambert, B. L., Mattison, J. E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.880784 · Cited by 25
Glucose-6-phosphate dehydrogenase deficiency and long-term risk of immune-related disorders
Israel, A., Schäffer, A. A., Berkovitch, M., Ozeri, D. J., Merzon, E., Green, I., Golan‐Cohen, A., Ruppin, E., Vinker, S., & Magen, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1232560 · Cited by 24
Self-citationMatveeva, O. V., & Ershov, A. (2022) · Vaccines · doi:10.3390/vaccines10070984 · Cited by 19
Changing Patterns of SARS-CoV-2 Seroprevalence among Canadian Blood Donors during the Vaccine Era
Reedman, C. N., Drews, S. J., Yi, Q., Pambrun, C., & O’Brien, S. F. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00339-22 · Cited by 20
Covid-19 vaccines, immunity, and boosters
Richterman, A. G., Scott, J. A., & Çevik, M. (2021) · BMJ · doi:10.1136/bmj.n3105 · Cited by 20
Hitchings, M. D. T., Ranzani, O., Lind, M. L., Dorión, M., D’Agostini, T. L., de Paula, R. C., de Paula, O. F. P., Villela, E. F. D. M., Torres, M. S. S., de Oliveira, S. B., et al. (2022) · BMJ · doi:10.1136/bmj-2022-070102 · Cited by 18
Durability analysis of the highly effective BNT162b2 vaccine against COVID-19
Puranik, A., Lenehan, P. J., O’Horo, J. C., Pawlowski, C., Niesen, M. J. M., Virk, A., Swift, M. D., Kremers, W. K., Venkatakrishnan, A., Gordon, J. E., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac082 · Cited by 16
The repeated setbacks of HIV vaccine development laid the groundwork for SARS-CoV-2 vaccines
Harris, J. E. (2022) · Health Policy and Technology · doi:10.1016/j.hlpt.2022.100619 · Cited by 16
Ishii, T., Hamada, K., Jubishi, D., Hashimoto, H., Okamoto, K., Hisasue, N., Sunohara, M., Saito, M., Shinohara, T., Yamashita, M., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-36397-6 · Cited by 15
COVID Vaccination as a Strategy for Cardiovascular Disease Prevention
Fundora, M. P., Kamidani, S., & Oster, M. E. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01950-2 · Cited by 13
SARS-CoV-2 Vaccines: The Advantage of Mucosal Vaccine Delivery and Local Immunity
Tobias, J., Steinberger, P., Wilkinson, J., Klais, G., Kundi, M., & Wiedermann, U. (2024) · Vaccines · doi:10.3390/vaccines12070795 · Cited by 15
Fougeroux, C. E., Hagen, S. H., Goksøyr, L., Aves, K.-L., Okholm, A. K., Morin, C., Lokras, A. G., Baghel, S. S., Foged, C., van de Vegte‐Bolmer, M., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01889-1 · Cited by 15
Dulovic, A., Kessel, B., Harries, M., Becker, M., Ortmann, J., Griesbaum, J., Juengling, J., Junker, D., Hernández, P., Gornyk, D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.828053 · Cited by 12
Nurchis, M. C., Lontano, A., Pascucci, D., Sapienza, M., Marziali, E., Castrini, F., Messina, R., Regazzi, L., Causio, F. A., Pilla, A. D., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19137848 · Cited by 12
Mazagatos, C., Delgado‐Sanz, C., Monge, S., Pozo, F., Oliva, J. A., Sandonis, V., Gandarillas, A., Rubio, C. Q., Ruiz‐Sopeña, C., García, V. G., et al. (2022) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13026 · Cited by 12
An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamsters
Zhang, Y., Wu, Y., Zhang, M., Rao, H., Zhang, Z., He, X., Liang, Y., Guo, R., Yuan, Y., Sun, J., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01155-4 · Cited by 12
Andrews, N. J., Stowe, J., Kirsebom, F. C. M., Toffa, S., Sachdeva, R., Gower, C., Ramsay, M. E., & Bernal, J. L. (2022) · Nature Medicine · doi:10.1038/d41591-022-00013-3 · Cited by 11
Risk of and duration of protection from SARS-CoV-2 reinfection assessed with real-world data
Reynolds, S. L., Kaufman, H. W., Meyer, W. A., Bush, C., Cohen, O. J., Cronin, K. A., Kabelac, C. A., Leonard, S., Anderson, S., Petkov, V. I., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0280584 · Cited by 13
Kosiorek, P., Kazberuk, D., Hryniewicz, A., Milewski, R. J., Stróż, S., & Stasiak‐Barmuta, A. (2022) · Vaccines · doi:10.3390/vaccines10020334 · Cited by 11
Muñoz-Alía, M. Á., Nace, R. A., Balakrishnan, B., Zhang, L., Packiriswamy, N., Singh, G., Warang, P., Mena, I., Narjari, R., Vandergaast, R., et al. (2024) · mBio · doi:10.1128/mbio.02928-23 · Cited by 12
du Preez, H. N., Lin, J., Maguire, G. E. M., Aldous, C. M., & Kruger, H. G. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14296 · Cited by 12
Hwang, M.-J., Hwang, I., Park, C., Park, H., Son, T., & Kim, J. (2022) · Epidemiology and Health · doi:10.4178/epih.e2023007 · Cited by 9
Ríos, S. S., Zamora, E. B. C., Céspedes, A. A., Rizos, L. R., Sánchez‐Jurado, P. M., Nievas, G. S., Romero, M. M., Sahuquillo, M. T. T., Señalada, J. J. B., Romero, A. M., et al. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17620 · Cited by 10
Fiori, M., Bello, G., Wschebor, N., Lecumberry, F., Ferragut, A., & Mordecki, E. (2022) · Scientific Reports · doi:10.1038/s41598-022-10896-4 · Cited by 10
Fair and effective vaccine allocation during a pandemic
Erdoğan, G., Yücel, E., Kiavash, P., & Salman, F. S. (2024) · Socio-Economic Planning Sciences · doi:10.1016/j.seps.2024.101895 · Cited by 9
Vaccine third dose and cancer patients: necessity or luxury?
Παππάς, Γ., Saloustros, E. S., Boutis, A. L., Tsoukalas, N., Nikolaou, M., Christopoulou, A. N., Agelaki, S., Boukovinas, I., Ardavanis, A., & Saridaki, Z. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100306 · Cited by 9
Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results
Agrati, C., Castilletti, C., Battella, S., Cimini, E., Matusali, G., Sommella, A., Sacchi, A., Colavita, F., Contino, A. M., Bordoni, V., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00531-8 · Cited by 9
Delay between COVID-19 complete vaccination and SARS-CoV-2 infection among healthcare workers
Saade, A., Cha, L., Tadié, É., Jurado, B., Bihan, A. L., Baron-Latouche, P., Fébreau, C., Thibault, V., Garlantézec, R., Tattevin, P., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.045 · Cited by 9
Horváth, J. K., Ferenci, T., Ferenczi, A., Túri, G., Röst, G., & Oroszi, B. (2022) · Vaccines · doi:10.3390/vaccines10111824 · Cited by 11
Epidemiology of clinically significant migraine in Israel: a retrospective database study
Shifrin, A., Domany, E., Tirosh, M., Davidovici, D., Vinker, S., Forschner, I., & Israel, A. (2025) · The Journal of Headache and Pain · doi:10.1186/s10194-025-01961-0 · Cited by 8
Self-citationLiu, C., Zhang, J., Zeng, Y., Huang, C., Chen, F., Cao, Y., Wu, S., Wei, D., Lin, Z., Zhang, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28280 · Cited by 6
Bosworth, M. L., Schofield, R., Ayoubkhani, D., Charlton, L., Nafilyan, V., Khunti, K., Zaccardi, F., Gillies, C., Akbari, A., Knight, M., et al. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000403 · Cited by 8
Rojas-Botero, M. L., Fernández-Niño, J. A., Arregocés-Castillo, L., Palacios-Clavijo, A. F., Pinto-Álvarez, M., & Gómez, F. R. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001845 · Cited by 8
Vaccinating against a Novel Pathogen: A Critical Review of COVID-19 Vaccine Effectiveness Evidence
Black, B. S., & Thaw, D. B. (2023) · Microorganisms · doi:10.3390/microorganisms12010089 · Cited by 9
Israel, A., Schäffer, A. A., Merzon, E., Green, I., Magen, E., Golan‐Cohen, A., Vinker, S., & Ruppin, E. (2022) · Microorganisms · doi:10.3390/microorganisms10061238 · Cited by 9
Self-citationCaserotti, M., Gavaruzzi, T., Girardi, P., Sellaro, R., Rubaltelli, E., Tasso, A., & Lotto, L. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.016 · Cited by 8
Niesen, M. J. M., Matson, R., Puranik, A., O’Horo, J. C., Pawlowski, C., Vachon, C. M., Challener, D. W., Virk, A., Swift, M. D., Speicher, L. L., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac042 · Cited by 7
SARS-CoV-2-Induced Immunosuppression: A Molecular Mimicry Syndrome
Kanduc, D. (2022) · Global Medical Genetics · doi:10.1055/s-0042-1748170 · Cited by 7
Bhagavathula, A. S., Mahabadi, M. A., Tesfaye, W. H., Nayar, K. R., & Chattu, V. K. (2022) · Healthcare · doi:10.3390/healthcare10030438 · Cited by 7
Ahmed‐Belkacem, A., Redjoul, R., Brillet, R., Ahnou, N., Leclerc, M., Molina, D. S. L., Soulier, A., Gourgeon, A., Rodriguez, C., Maury, S., et al. (2022) · Viruses · doi:10.3390/v14091928 · Cited by 6
Wu, F., Guo, Z., Yang, J., Ou, Y., Xie, X., Liao, H., Guo, C., Zhan, Y., Wu, H., Hu, R. M., et al. (2025) · Advanced Materials · doi:10.1002/adma.202412430 · Cited by 8
Lopez, M. V., Vinzón, S. E., Cafferata, E. G. A., Núñez, F. J., Soto, A. S., Sánchez‐Lamas, M., Afonso, M. J., Aguilar-Cortes, D. C., Ríos, G. D., Maricato, J. T., et al. (2021) · Vaccines · doi:10.3390/vaccines9101106 · Cited by 6
Al‐Akioui‐Sanz, K., Pascual-Miguel, B., Díaz‐Almirón, M., Mestre‐Durán, C., Navarro‐Zapata, A., Villa, L. C., Martín-Cortázar, C., Vicario, J. L., Moreno, M. Á., Balas, A., et al. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.12.001 · Cited by 5
Tamura, M., Fujita, R., Sato, T., Sato, R., Kato, Y., Nagasawa, M., & Matsumoto, T. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.07.006 · Cited by 6
Evaluation of BNT162b2 vaccine effectiveness in Malaysia: test negative case-control study
Lim, A. H., Rahman, N. A., Ong, S. M., Paraja, J., Rashid, R., Parmar, I. S., Dahlan, S. N., Tan, Z. S. S., Bohari, I., Peariasamy, K. M., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.032 · Cited by 6
Sawaid, I. O., Din, Z., Golan, E., Ruppin, E., Golan‐Cohen, A., Green, I., Merzon, E., Vinker, S., Samson, A. O., & Israel, A. (2026) · PLoS Medicine · doi:10.1371/journal.pmed.1004842 · Cited by 5
Self-citationJiang, J., Lau, E. H. Y., Zhou, Z., Yin, G., Lin, Y., Cowling, B. J., & Lam, K. F. (2024) · Vaccines · doi:10.3390/vaccines12091014 · Cited by 6
Prediction of COVID-19 infection spread through agent-based simulation
An, T., Kim, H., & Joo, C. (2022) · ACM International Symposium on Theory, Algorithmic Foundations, and Protocol Design for Mobile Networks and Mobile Computing (MobiHoc) · doi:10.1145/3492866.3557735 · Cited by 5
Park, H., Park, Y.-J., Lee, S., Lee, M. J., & Ahn, H. (2022) · Osong Public Health and Research Perspectives · doi:10.24171/j.phrp.2022.0243 · Cited by 5
Wolszczak-Biedrzycka, B., Bieńkowska, A., Cieślikiewicz, B., Smolińska-Fijołek, E., Biedrzycki, G., & Dorf, J. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2182907 · Cited by 7
Sansone, E., Collatuzzo, G., Renzetti, S., Ditano, G., Bonfanti, C., Sala, E., Terlenghi, L., Matteelli, A., Abedini, M., Asafo, S. S., et al. (2023) · Vaccines · doi:10.3390/vaccines11040746 · Cited by 5
Jiang, J., Lam, K. F., Lau, E. H. Y., Yin, G., Lin, Y., & Cowling, B. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-89043-8 · Cited by 5
Metadata
- Authors
- Israel, A., Merzon, E., Schäffer, A. A., Shenhar, Y., Green, I., Golan-Cohen, A., Ruppin, E., Magen, E., & Vinker, S.
- Affiliations
- Leumit Health Services, Tel Aviv, Israel
- Tel Aviv University (IL)
- National Institutes of Health (US)
- Ben-Gurion University of the Negev (IL)
- Corresponding author
- Israel, Ariel
- ORCID
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2021-11-24
- Volume
- 375
- Pages
- e067873
- ISSN
- 1756-1833 (ISSN-L)
- PMC
- PMC9083235
- OpenAlex
- W3216422624
- Cited by
- 170
- References
- 24
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 19 · 2023: 30 · 2022: 73 · 2021: 30
- FWCI
- 12.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- BMJ (publishedVersion, cc-by-nc)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- Funders
- U.S. Department of Health and Human Services
- National Institutes of Health
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- BNT162b2, mRNA vaccines, COVID-19 pandemic, waning vaccine effectiveness, breakthrough infection, vaccine protection duration, ultra-Orthodox Jews, Arab ancestry, Israel
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
